Purpose This paper assesses the design of clinical studies used in the process of regulatory approval, focusing on how add-on studies affect regulatory decisions. Methods The sample case taken is that of the new agents for rheumatoid arthritis (RA) authorised by the European Medicine Agency (EMEA). The European Public Assessment Reports (EPARs) accompanying the marketing authorisations were the source of information on the studies presented in the registration dossiers. Results The recently approved anti-RA agents are all indicated in combination with methotrexate (MTX) for treating adults with active RA who have responded inadequately to diseasemodifier drugs (DMARDs). The add-on design was frequently used in registration studies. For infliximab, etanercept, adalimumab and rituximab, add-on trials contributed, together with parallel-group trials, to gaining the approval as combination therapy. Anakinra and abatacept were authorised on the basis of add-on trial results only. Conclusions Add-on trials do not allow assessment of the intrinsic efficacy and safety of new agents and their value as alternatives to available treatments. The indications granted for the new anti-RA agents do not specify whether newer drugs can replace standard treatments in nonresponders, can do better in the overall patient population or can be used as first-line treatment.
increase efficacy without increasing toxicity in multifactorial diseases such as diabetes, hypertension, etc. This is the case with rheumatoid arthritis (RA) also, in which patient responses to standard treatments tend to vary. The European Medicine Agency (EMEA) guidelines of 2003 (CPMP/ EWP/556/95 rev1/Final) recommend that approval of new antirheumatic drugs for RA should be based on proof of efficacy from adequately designed parallel group randomised trials against placebo, or comparative studies against an established active comparator. Combination therapy is also accepted, as this strategy "is gaining popularity", provided that therapeutic claims, pharmacological rationale and investigation on drug interactions are presented. "Addon placebo therapy may also be used when study design requires placebo and allows for combination with other effective treatment". Following on from our previous critical evaluation of regulatory criteria for marketing approval of antirheumatic drugs [1] , this paper focuses on how add-on studies influence regulatory decisions, examining the design of clinical studies used in the process of EMEA regulatory approval of new anti-RA agents.
Methods
Information on each anti-RA drug approved by the EMEA from 1995 to 2007 was collected from the European Public Assessment Reports (EPARs), Scientific Summary (www. emea.europa.eu/index/indexh1.htm), and completed with the published papers on the trials that provided the basis for approval. These trials were reviewed with particular attention to study design, type of comparator used, combination therapy and inclusion criteria and are grouped according to the comparators used or their combinations.
Results
Seven anti-RA [one nonbiological, three tumour necrosis factor (TNF)-α blockers-infliximab (IFX), etanercept (ETN) and adalimumab (ADL)-the interleukin (IL)-1 blocker anakinra (ANK), the anti-CD20 antibody rituximab (RTM) and the selective co-stimulation modulator abatacept (ABA] were granted a marketing authorisation (MA) by the EMEA. Table 1 reports the main characteristics of the pivotal clinical studies submitted to EMEA: leflunomide (LFE) [2], the only nonbiological disease modifying antirheumatic drug (DMARD) and the first to be approved (1999), was authorised on the basis of four phase III trials [3] [4] [5] [6] including placebo and active controls [methotrexate (MTX) and sulphasalazine (SSZ)], although only superiority over placebo was demonstrated.
ETN [7] gained approval in 2000 as monotherapy or in combination with MTX in patients inadequately responding to a DMARD, with two phase III studies vs. placebo [8, 9] and one phase II/III add-on study [10] . Indication for treatment (in combination with MTX) of early RA patients not previously treated with MTX followed in 2004, with two phase III studies [11, 12] comparing ETN and MTX and with the combination of the new agent and MTX. An add-on study supported approval of the 50-mg strength (2005) [13] .
The clinical trial programme for the initial authorisation (2000) of IFX [14] encompassed six clinical studies, the pivotal one being a phase III add-on study [15] , which demonstrated the superiority of the combination in active RA patients inadequately responding to a DMARD (MTX). The extension of indication for early RA in patients not previously treated with MTX or other DMARDs (2001) was based on one clinical trial [16] comparing the combination of IFX and MTX with MTX plus placebo in MTX-naïve patients.
ADL [17] was approved in 2002 for treating patients inadequately responding to MTX on the basis of four studies, two that were placebo-controlled [18] ; one primarily a safety study; and two add-on trials [19, 20] . In MTXnaïve patients, a phase III RCT supported the combination of ADL and MTX (2005) [21] .
ANK [22] in combination with MTX received approval (2002) on the basis of two add-on randomised clinical trials (RCTs) [23, 24] and one dose-finding study lasting 24 weeks (not reported in Table 1 ).
RTM [25] in combination with MTX is indicated for severe active RA in patients inadequately responding or intolerant to DMARDs, including one or more TNF inhibitors (2006) . The clinical programme included one phase III add-on trial and two supportive phase II studies: one comparative vs. MTX and one add-on.
ABA [26] , the latest to be approved (2007), with an indication similar to RTM, presented a clinical development programme including three studies providing the main efficacy data and three with additional efficacy/safety information: a phase IIA pilot dose-finding monotherapy (not reported in Table 1 ), a phase IIB exploratory, and a phase III study. One further pivotal trial was submitted during evaluation of the MA application. As stated in the EPAR, it was designed "to validate the efficacy responses and to directly compare the safety profile of ABA-MTX and IFX-MTX combinations and placebo rather than to demonstrate noninferiority or superiority of ABA compared to infliximab". In all studies, ABA was tested as add-on to background therapy with MTX, DMARDs or anti-TNF.
On the whole, comparison with placebo was the topic of four trials, mainly dose ranging, of ETN and ADL (Table 2) . LFE (four studies) and ETN (one) were compared with but The add-on design was the most frequent approach used in the approval process of new biologic response modifiers. Three strategies were used in combination therapy in RA: "parallel" (multiple treatments are administered concurrently), "step-up" (addition of a DMARD to the background of another, partially effective, DMARD) and "step-down" (concomitant DMARDs sequentially withdrawn once benefit has been achieved) [27] . For four agents (IFX, ETN, ADL and RTM) the add-on trials contributed to obtaining approval as combination therapy, whereas ANK and ABA were authorised only on the data of add-on trials.
The new biologic agents are all indicated (Table 2) in combination with MTX for treating adult patients with active RA inadequately responding to previous DMARDs, including MTX and one or more TNF inhibitors, such as RTM and ABA. ADL is approved for monotherapy only in case of intolerance to MTX or when continued treatment with MTX is inappropriate.
A further critical issue in the process of approval of new agents is pharmacokinetic drug interactions. Table 3 summarises the pharmacokinetic and interaction studies reported in the EPAR. Routine pharmacokinetic studies were produced for each new agent, but formal studies on interactions were either generally limited (MTX raised plasma concentrations of IFX, did not modify the kinetics of RTM and ETN; the influence of ETN on MTX was not investigated) or neglected, as in the case of concomitant background therapy. Only clinical evidence of toxicity in patients concurrently receiving two TNF antagonists led to the warning not to use such combinations.
Discussion
Our survey found that add-on trials had an important role in the approval process of the newer antirheumatic agents, possibly because this approach easily provides a demonstration of efficacy. In the last few years, the comparison of a new drug or placebo added to ongoing DMARD treatment has become the standard trial design, with MTX being the standard DMARD [28, 29] , in a population of socalled partial responders.
Add-on trials are reported to have some practical advantages (absence of flares, similarity to daily practice, benefits of maintenance of concomitant drugs, proof of concept accepted by regulatory agencies). However, data on the superiority of combination DMARD therapy in RA are controversial [30] because of confounding factors. These include inadequate definition of incomplete responders to previous/concomitant DMARDs, quite low percentages of patients without adequate response to MTX and background therapy (NSAIDs, glucocorticoids) not considered a part of the add-on combination [31] [32] [33] . Trend to decreasing Cl with increasing age.
Slightly higher % of infectious SAEs in ADL patients taking corticosteroids
No gender differences.
anakinra Basic parameters subcutaneous and intravenous injection.
No evidence of interactions with NSAIDs or corticosteroids (no studies)
Not to be used in severe renal insufficiency Elimination route not studied.
Combination with any other TNF antagonist not recommended (increased risk of serious infections)
Cl: no effect of gender or age; reduced in hepatic impairment; no studies in severe insufficiency In phase III co-administered MTX, corticosteroids, NSAIDs, anti-TNF no influence on ABA Cl.
No studies in special populations
Some of the drawbacks reported in the literature show up in the add-on studies included in this review ( Table  1) . The inclusion criteria of the add-on trials submitted to the EMEA show the heterogenicity of the patient populations enrolled (suboptimal response to one or more DMARD, duration, type and dosages of background therapy, with or without washout period, etc.). In the majority of the add-on trials, patients had very active disease and were "inadequate" or "partial" responders to MTX or anti-TNF agents. Another point for concern is the failure to report detailed information about the number and dosage and possible interactions of concomitant background medications, specifically NSAIDs and corticosteroids, which are anti-inflammatory agents with their own efficacy and toxicity. Another disadvantage of this design is that it can be potentially harmful, as shown by the negative experience with combined ANK and ETN [34] and the exploratory phase IIB study adding ABA to ETN [35] .
The main concern, however, regards the use of placebo in patients with a poor response to current treatment. If the treatment is definitively ineffective, it should not be continued in either treatment group, as it would be useless and therefore unethical. If it is partially effective, adding placebo in one arm while providing an active drug in the other would be unethical too. It is advisable in any case to compare two active treatments, as either an alternative or an add-on to the current unsatisfactory therapies. Comparing one treatment against two seems an uneven challenge, it being possibly easier for the new drug together with the standard treatment to perform better than the latter alone. Moreover, this approach does not provide adequate information on how the test drug added on top of ongoing therapies fares in comparison with other treatments.
The lack of direct comparisons between new active principles makes it difficult to choose among so many alternatives. Ideally, it would be useful to compare any new agent with the best current treatment and with their combination (A vs. B vs. A + B, than A vs. C vs. A + C, and so on). In view of the lack of direct comparisons of newly approved anti-RA, it is difficult to identify the "gold standard" of treatment on top of MTX with which a new compound should be compared. From a historical point of view, the first approved agent, LFE, should have served as comparator for the next ones, namely IFX and ETN. Combinations should also be compared with each other. In the approval process, the true value of the new agent alone and in combination should be assessed through superiority clinical trials.
The pharmacokinetic drug interactions studies, which do not actually seem to be considered very important, are in fact needed because research on interactions could be helpful in developing rational combination therapy with less toxicity. These studies would also show whether apparently better efficacy of the add-on approach is merely due to a higher concentration of one or the other component of the combination.
In conclusion, the add-on approach is popular for registration purposes, as it offers many practical, financial (savings in time and investment and exempting the sponsor from correct comparisons) and theoretical advantages, mirrors clinical practice and substantially demonstrates the efficacy of a combination. This design, however, does not provide firm proof that any effect observed really relates to the combination, as the control arm is so often a placebo in patients with active disease despite treatment with MTX or other background therapy, so it is difficult to assess the intrinsic efficacy and safety of the new agent and its value as an alternative to current remedies. The indications granted do not indicate whether newer drugs can replace standard treatments in nonresponders and even less whether they can do better. Nor do they say which of them must come first, if any.
This review of the clinical data submitted to the EMEA indicates that to obtain approval easily, no comparative studies between the new biologic anti-RA agents were done, even though efficacy patterns seem to be similar and a direct comparison would have been possible, at least after the MA. Surprisingly, not even equivalence or noninferiority trials against the best available treatment were done. As uncontrolled trials artificially set up in the late stages of diseases, placebocontrolled trials and equivalence or noninferiority trials, the add-on approach complies with the European Pharma law [36] , which allows each drug to be approved on the basis of its own quality, safety and efficacy, with no need for comparison with active comparators. Legislators and regulatory authorities could usefully redesign regulations and registration trial requirements, as suggested above, with a view to obtaining unequivocal data about the comparative efficacy and safety of current and newer drugs, including anti-RA agents, which would best meet the needs of the clinical community.
